Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOLON, Israel, Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at from Monday, September 9, 2024, 7:00 AM ET for 30 days.
伊斯特爾港，以色列，2024年8月29日/美通社/ - compugen醫療 ltd。 (納斯達克: CGEN) (泰斯: CGEN)，一家臨床階段的癌症免疫療法公司，也是計算目標發現的先驅者，今天宣佈管理層將在線上出席 H.C. Wainwright第26屆年度全球投資大會。相關演講將從2024年9月9日星期一7:00 Am Et供應30天，持有人可在compugen醫療的網站投資者關係部分隨時觀看。
About Compugen
關於Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
compugen醫療是一家臨床階段的治療發現和開發公司，利用其廣泛適用的預測計算發現能力來尋找開發癌症免疫療法的新藥靶標和生物途徑。compugen醫療開發的兩個自有產品候選品正在進行1期開發: COM701是潛在的首個PVRIG抗體，COM902是潛在的最佳TIGIt靶標抗體，用於治療固體腫瘤。rilvegostomig是一種PD-1/TIGIt雙特異抗體，其中TIGIt組分來自於compugen醫療的臨床階段抗TIGIt抗體COM902，通過與阿斯利康公司的許可協議進行雙特異性和多特異性抗體的開發，在3期開發中。此外，該公司早期免疫腫瘤學計劃的治療性管線涉及針對免疫抵抗的各種機制的項目，其中最先進的項目是COM503，這是一種潛在的首個高親和力抗IL-18結合蛋白抗體，已獲得美國食品藥品監督管理局的IND清關，已獲得吉利德公司的許可。compugen醫療總部位於以色列，在加利福尼亞州舊金山設有辦事處。compugen醫療的股票在納斯達克和特拉維夫證券交易所上市，股票代碼爲CGEN。
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
公司聯繫方式：
Yvonne Naughton博士
投資者關係和企業溝通負責人
電子郵件：[email protected]
電話：+1 (628) 241-0071
SOURCE Compugen Ltd.
消息來源：Compugen Ltd.
譯文內容由第三人軟體翻譯。